2 terminated, 1 active not recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Active not recruiting 1 |
Follow Deupirfenidone: new trials by email Literature Review of Deupirfenidone trials Research Report on Deupirfenidone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Placebo, Pirfenidone, Deupirfenidone - Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | PureTech | 240 | 2022-07-22 | 2025-10-16 |
| LYT-100 in Post-acute COVID-19 Respiratory Disease LYT-100, Placebo - Covid19, Post-acute COVID-19 Respiratory Disease | Phase 2 | Terminated | PureTech | 185 | 2020-12-11 | 2026-06-23 |
| LYT-100 in Patients With BCRL LYT-100 BCRL, Placebo BCRL - Breast Cancer Related Lymphoedema, Lymphoedema | Phase 2 | Terminated | PureTech | 50 | 2020-03-01 | 2024-04-23 |
Pulmonary Fibrosis (2) · COVID-19 (1) · Idiopathic Pulmonary Fibrosis (1) · Lung Diseases, Interstitial (1) · Lymphedema (1) · Post-Acute COVID-19 Syndrome (1) · Respiration Disorders (1)
PureTech (3)
United States (3) · Argentina (2) · Philippines (2) · Romania (2) · Australia (1) · Brazil (1) · Chile (1) · Colombia (1) · Georgia (1) · Greece (1) · India (1) · Malaysia (1) · Mexico (1) · Moldova (1) · South Africa (1)
Camilla Graham, MD (1) · Toby Maher, MD (1)